Experience with Octreotide in patients with castration refractory prostate cancer

被引：0
|
作者：
Ganov, D. I. [1 ]
Varlamov, S. A. [1 ]
机构：
[1] Altai State Med Univ, Kussian Acad Med Sci, NN Blokhin Russian Canc Res Ctr, Altai Branch, Barnaul, Russia
来源：
ONKOUROLOGIYA | 2011年 / 7卷 / 04期
关键词：
castration refractory prostate cancer; sustained-release octreotide;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Fifteen patients with castration refractory prostate cancer have been treated with sustained-release octreotide in combination with dexamethasone at the Altai Territory Oncology Dispensary since 2008. Control PSA test revealed that 9 (60 %) patients had positive changes; tumor process stabilization was noted in 4 (26.7 %) and only 2 (13.3 %) were found to have disease progression. Thus, more than 86 % of patients responded to combination treatment with sustained-release octreotide + dexamethasone. Octreotide treatment caused no serious specific adverse toxic reactions.
引用
收藏
页码：71 / 73
页数：3
相关论文
共 50 条
  • [21] Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer
    K M Kalkner
    S Acosta
    O Thorsson
    H Frederiksen
    A Nilsson
    B Gustavsson
    M Elingsbo
    M Stridsberg
    P-A Abrahamsson
    Prostate Cancer and Prostatic Diseases, 2006, 9 : 92 - 98
  • [22] Current possibilities of treatment for visceral metastases in patients with metastatic castration-refractory prostate cancer
    Govorov, A. V.
    Moiseenko, T. N.
    ONKOUROLOGIYA, 2013, 9 (02): : 53 - 56
  • [23] Third-line Therapy for Patients with metastatic castration-refractory Prostate Cancer (mCRPC)
    Rexer, H.
    Hammerer, P.
    Merseburger, A.
    AKTUELLE UROLOGIE, 2019, 50 (02) : 144 - 145
  • [24] TREATMENT OF CASTRATION REFRACTORY PROSTATE CANCER PATIENTS WITH 2 DIFFERENT IMMUNOTHERAPEUTIC APPROACHES AGAINST EGFR
    Crombet, T.
    Gonzalez, J.
    Gonzalez, J.
    Bouzo, A.
    Gracia, B.
    Popa, X.
    Mendoza, I.
    Ills, D.
    Lage, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 165 - 165
  • [25] Neuroendocrine markers as predictor of octreotide acetate therapy in patients with hormone-refractory prostate cancer.
    Acosta, S
    Kälkner, KM
    Thorsson, O
    Fredriksson, M
    Nilsson, A
    Gustavsson, B
    Elingsbo, M
    Stridsberg, M
    Abrahamsson, PA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 443S - 443S
  • [26] Effect of chemotherapy on somatostatin receptor detection with octreotide scintigraphy in hormone-refractory prostate cancer patients
    Mencoboni, M
    Tredici, S
    Rebella, L
    Bergaglio, M
    Galbusera, V
    Manzara, A
    Claudiani, F
    Malcangi, B
    Varaldo, M
    ANTICANCER RESEARCH, 2006, 26 (3B) : 2233 - 2235
  • [27] Metastasis-directed therapy for oligoprogressive castration refractory prostate cancer
    Berghen, C.
    Joniau, S.
    Ost, P.
    Poels, K.
    Everaerts, W.
    Haustermans, K.
    De Meerleer, G.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S451 - S451
  • [28] Modular therapy approach in metastatic castration-refractory prostate cancer
    B. Walter
    S. Rogenhofer
    M. Vogelhuber
    A. Berand
    W. F. Wieland
    R. Andreesen
    A. Reichle
    World Journal of Urology, 2010, 28 : 745 - 750
  • [29] Change of the LHRH analogue in progressive castration-refractory prostate cancer
    Heidenreich, A.
    Porres, D.
    Epplen, R.
    van Erps, T.
    Pfister, D.
    UROLOGE, 2012, 51 (09): : 1282 - 1287
  • [30] Castration-Refractory Prostate Cancer: New Therapies, New Questions
    Appleman, Leonard J.
    ONCOLOGY-NEW YORK, 2010, 24 (14): : 1318 - 1326
12345